Research ArticleArticle
Open Access
Anti-HMGCR Autoantibodies in Juvenile Idiopathic Inflammatory Myopathies Identify a Rare but Clinically Important Subset of Patients
Sarah L. Tansley, Zoe E. Betteridge, Stefania Simou, Thomas S. Jacques, Clarissa Pilkington, Mark Wood, Kishore Warrier, Lucy R. Wedderburn and Neil J. McHugh on behalf of the Juvenile Dermatomyositis Research Group
The Journal of Rheumatology February 2017, jrheum.160871; DOI: https://doi.org/10.3899/jrheum.160871
Sarah L. Tansley
From the Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust; University of Bath, Bath; University College London (UCL) Institute of Child Health; Arthritis Research UK Centre for Adolescent Rheumatology at UCL, University College London Hospitals (UCLH), and Great Ormond Street Hospital (GOSH), London; Leeds Children’s Hospital, Leeds; Nottingham University Hospitals UK National Health Service (NHS) Trust, Nottingham, UK. Funding for the UK Juvenile Dermatomyositis Cohort and Biomarker study has been provided by the Wellcome Trust UK (085860), Action Medical Research UK (SP4252), The Myositis Support Group UK, Arthritis Research UK (14518, 20164), The Henry Smith Charity and Great Ormond Street Children’s Charity (V1268), and the National Institute for Health Research (NIHR) Translational Research Collaboration Rare Diseases. This research was supported by the NIHR Biomedical Research Centre at GOSH for Children NHS Foundation Trust and Institute of Child Health UCL. SLT is supported by a fellowship from The Bath Institute for Rheumatic Diseases and has received previous support from the BMA Doris Hillier Grant (2012). S.L. Tansley, MBChB, MRCP, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust, and University of Bath; Z.E. Betteridge, BSc, PhD, University of Bath; S. Simou, MSc, UCL Institute of Child Health; T.S. Jacques, PhD, MRCP, FRCPath, UCL Institute of Child Health, and GOSH; C. Pilkington, MBBS, FRCPCH, FRCP, GOSH; M. Wood, MBBS, MRCPCH, Leeds Children’s Hospital; K. Warrier, MBBS, MRCPCH, Nottingham University Hospitals NHS Trust; L.R. Wedderburn, MD, PhD, FRCP, UCL Institute of Child Health, and GOSH, and Arthritis Research UK Centre for Adolescent Rheumatology at UCL, UCLH, and GOSH; N.J. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust, and University of Bath. Address correspondence to Dr. S.L. Tansley, Royal National Hospital For Rheumatic Diseases NHS Foundation Trust, Upper Borough Walls, Bath BA1 1RL, UK. E-mail: s.tansley@nhs.net. Accepted for publication December 23, 2016.
Zoe E. Betteridge
From the Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust; University of Bath, Bath; University College London (UCL) Institute of Child Health; Arthritis Research UK Centre for Adolescent Rheumatology at UCL, University College London Hospitals (UCLH), and Great Ormond Street Hospital (GOSH), London; Leeds Children’s Hospital, Leeds; Nottingham University Hospitals UK National Health Service (NHS) Trust, Nottingham, UK. Funding for the UK Juvenile Dermatomyositis Cohort and Biomarker study has been provided by the Wellcome Trust UK (085860), Action Medical Research UK (SP4252), The Myositis Support Group UK, Arthritis Research UK (14518, 20164), The Henry Smith Charity and Great Ormond Street Children’s Charity (V1268), and the National Institute for Health Research (NIHR) Translational Research Collaboration Rare Diseases. This research was supported by the NIHR Biomedical Research Centre at GOSH for Children NHS Foundation Trust and Institute of Child Health UCL. SLT is supported by a fellowship from The Bath Institute for Rheumatic Diseases and has received previous support from the BMA Doris Hillier Grant (2012). S.L. Tansley, MBChB, MRCP, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust, and University of Bath; Z.E. Betteridge, BSc, PhD, University of Bath; S. Simou, MSc, UCL Institute of Child Health; T.S. Jacques, PhD, MRCP, FRCPath, UCL Institute of Child Health, and GOSH; C. Pilkington, MBBS, FRCPCH, FRCP, GOSH; M. Wood, MBBS, MRCPCH, Leeds Children’s Hospital; K. Warrier, MBBS, MRCPCH, Nottingham University Hospitals NHS Trust; L.R. Wedderburn, MD, PhD, FRCP, UCL Institute of Child Health, and GOSH, and Arthritis Research UK Centre for Adolescent Rheumatology at UCL, UCLH, and GOSH; N.J. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust, and University of Bath. Address correspondence to Dr. S.L. Tansley, Royal National Hospital For Rheumatic Diseases NHS Foundation Trust, Upper Borough Walls, Bath BA1 1RL, UK. E-mail: s.tansley@nhs.net. Accepted for publication December 23, 2016.
Stefania Simou
From the Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust; University of Bath, Bath; University College London (UCL) Institute of Child Health; Arthritis Research UK Centre for Adolescent Rheumatology at UCL, University College London Hospitals (UCLH), and Great Ormond Street Hospital (GOSH), London; Leeds Children’s Hospital, Leeds; Nottingham University Hospitals UK National Health Service (NHS) Trust, Nottingham, UK. Funding for the UK Juvenile Dermatomyositis Cohort and Biomarker study has been provided by the Wellcome Trust UK (085860), Action Medical Research UK (SP4252), The Myositis Support Group UK, Arthritis Research UK (14518, 20164), The Henry Smith Charity and Great Ormond Street Children’s Charity (V1268), and the National Institute for Health Research (NIHR) Translational Research Collaboration Rare Diseases. This research was supported by the NIHR Biomedical Research Centre at GOSH for Children NHS Foundation Trust and Institute of Child Health UCL. SLT is supported by a fellowship from The Bath Institute for Rheumatic Diseases and has received previous support from the BMA Doris Hillier Grant (2012). S.L. Tansley, MBChB, MRCP, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust, and University of Bath; Z.E. Betteridge, BSc, PhD, University of Bath; S. Simou, MSc, UCL Institute of Child Health; T.S. Jacques, PhD, MRCP, FRCPath, UCL Institute of Child Health, and GOSH; C. Pilkington, MBBS, FRCPCH, FRCP, GOSH; M. Wood, MBBS, MRCPCH, Leeds Children’s Hospital; K. Warrier, MBBS, MRCPCH, Nottingham University Hospitals NHS Trust; L.R. Wedderburn, MD, PhD, FRCP, UCL Institute of Child Health, and GOSH, and Arthritis Research UK Centre for Adolescent Rheumatology at UCL, UCLH, and GOSH; N.J. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust, and University of Bath. Address correspondence to Dr. S.L. Tansley, Royal National Hospital For Rheumatic Diseases NHS Foundation Trust, Upper Borough Walls, Bath BA1 1RL, UK. E-mail: s.tansley@nhs.net. Accepted for publication December 23, 2016.
Thomas S. Jacques
From the Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust; University of Bath, Bath; University College London (UCL) Institute of Child Health; Arthritis Research UK Centre for Adolescent Rheumatology at UCL, University College London Hospitals (UCLH), and Great Ormond Street Hospital (GOSH), London; Leeds Children’s Hospital, Leeds; Nottingham University Hospitals UK National Health Service (NHS) Trust, Nottingham, UK. Funding for the UK Juvenile Dermatomyositis Cohort and Biomarker study has been provided by the Wellcome Trust UK (085860), Action Medical Research UK (SP4252), The Myositis Support Group UK, Arthritis Research UK (14518, 20164), The Henry Smith Charity and Great Ormond Street Children’s Charity (V1268), and the National Institute for Health Research (NIHR) Translational Research Collaboration Rare Diseases. This research was supported by the NIHR Biomedical Research Centre at GOSH for Children NHS Foundation Trust and Institute of Child Health UCL. SLT is supported by a fellowship from The Bath Institute for Rheumatic Diseases and has received previous support from the BMA Doris Hillier Grant (2012). S.L. Tansley, MBChB, MRCP, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust, and University of Bath; Z.E. Betteridge, BSc, PhD, University of Bath; S. Simou, MSc, UCL Institute of Child Health; T.S. Jacques, PhD, MRCP, FRCPath, UCL Institute of Child Health, and GOSH; C. Pilkington, MBBS, FRCPCH, FRCP, GOSH; M. Wood, MBBS, MRCPCH, Leeds Children’s Hospital; K. Warrier, MBBS, MRCPCH, Nottingham University Hospitals NHS Trust; L.R. Wedderburn, MD, PhD, FRCP, UCL Institute of Child Health, and GOSH, and Arthritis Research UK Centre for Adolescent Rheumatology at UCL, UCLH, and GOSH; N.J. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust, and University of Bath. Address correspondence to Dr. S.L. Tansley, Royal National Hospital For Rheumatic Diseases NHS Foundation Trust, Upper Borough Walls, Bath BA1 1RL, UK. E-mail: s.tansley@nhs.net. Accepted for publication December 23, 2016.
Clarissa Pilkington
From the Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust; University of Bath, Bath; University College London (UCL) Institute of Child Health; Arthritis Research UK Centre for Adolescent Rheumatology at UCL, University College London Hospitals (UCLH), and Great Ormond Street Hospital (GOSH), London; Leeds Children’s Hospital, Leeds; Nottingham University Hospitals UK National Health Service (NHS) Trust, Nottingham, UK. Funding for the UK Juvenile Dermatomyositis Cohort and Biomarker study has been provided by the Wellcome Trust UK (085860), Action Medical Research UK (SP4252), The Myositis Support Group UK, Arthritis Research UK (14518, 20164), The Henry Smith Charity and Great Ormond Street Children’s Charity (V1268), and the National Institute for Health Research (NIHR) Translational Research Collaboration Rare Diseases. This research was supported by the NIHR Biomedical Research Centre at GOSH for Children NHS Foundation Trust and Institute of Child Health UCL. SLT is supported by a fellowship from The Bath Institute for Rheumatic Diseases and has received previous support from the BMA Doris Hillier Grant (2012). S.L. Tansley, MBChB, MRCP, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust, and University of Bath; Z.E. Betteridge, BSc, PhD, University of Bath; S. Simou, MSc, UCL Institute of Child Health; T.S. Jacques, PhD, MRCP, FRCPath, UCL Institute of Child Health, and GOSH; C. Pilkington, MBBS, FRCPCH, FRCP, GOSH; M. Wood, MBBS, MRCPCH, Leeds Children’s Hospital; K. Warrier, MBBS, MRCPCH, Nottingham University Hospitals NHS Trust; L.R. Wedderburn, MD, PhD, FRCP, UCL Institute of Child Health, and GOSH, and Arthritis Research UK Centre for Adolescent Rheumatology at UCL, UCLH, and GOSH; N.J. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust, and University of Bath. Address correspondence to Dr. S.L. Tansley, Royal National Hospital For Rheumatic Diseases NHS Foundation Trust, Upper Borough Walls, Bath BA1 1RL, UK. E-mail: s.tansley@nhs.net. Accepted for publication December 23, 2016.
Mark Wood
From the Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust; University of Bath, Bath; University College London (UCL) Institute of Child Health; Arthritis Research UK Centre for Adolescent Rheumatology at UCL, University College London Hospitals (UCLH), and Great Ormond Street Hospital (GOSH), London; Leeds Children’s Hospital, Leeds; Nottingham University Hospitals UK National Health Service (NHS) Trust, Nottingham, UK. Funding for the UK Juvenile Dermatomyositis Cohort and Biomarker study has been provided by the Wellcome Trust UK (085860), Action Medical Research UK (SP4252), The Myositis Support Group UK, Arthritis Research UK (14518, 20164), The Henry Smith Charity and Great Ormond Street Children’s Charity (V1268), and the National Institute for Health Research (NIHR) Translational Research Collaboration Rare Diseases. This research was supported by the NIHR Biomedical Research Centre at GOSH for Children NHS Foundation Trust and Institute of Child Health UCL. SLT is supported by a fellowship from The Bath Institute for Rheumatic Diseases and has received previous support from the BMA Doris Hillier Grant (2012). S.L. Tansley, MBChB, MRCP, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust, and University of Bath; Z.E. Betteridge, BSc, PhD, University of Bath; S. Simou, MSc, UCL Institute of Child Health; T.S. Jacques, PhD, MRCP, FRCPath, UCL Institute of Child Health, and GOSH; C. Pilkington, MBBS, FRCPCH, FRCP, GOSH; M. Wood, MBBS, MRCPCH, Leeds Children’s Hospital; K. Warrier, MBBS, MRCPCH, Nottingham University Hospitals NHS Trust; L.R. Wedderburn, MD, PhD, FRCP, UCL Institute of Child Health, and GOSH, and Arthritis Research UK Centre for Adolescent Rheumatology at UCL, UCLH, and GOSH; N.J. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust, and University of Bath. Address correspondence to Dr. S.L. Tansley, Royal National Hospital For Rheumatic Diseases NHS Foundation Trust, Upper Borough Walls, Bath BA1 1RL, UK. E-mail: s.tansley@nhs.net. Accepted for publication December 23, 2016.
Kishore Warrier
From the Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust; University of Bath, Bath; University College London (UCL) Institute of Child Health; Arthritis Research UK Centre for Adolescent Rheumatology at UCL, University College London Hospitals (UCLH), and Great Ormond Street Hospital (GOSH), London; Leeds Children’s Hospital, Leeds; Nottingham University Hospitals UK National Health Service (NHS) Trust, Nottingham, UK. Funding for the UK Juvenile Dermatomyositis Cohort and Biomarker study has been provided by the Wellcome Trust UK (085860), Action Medical Research UK (SP4252), The Myositis Support Group UK, Arthritis Research UK (14518, 20164), The Henry Smith Charity and Great Ormond Street Children’s Charity (V1268), and the National Institute for Health Research (NIHR) Translational Research Collaboration Rare Diseases. This research was supported by the NIHR Biomedical Research Centre at GOSH for Children NHS Foundation Trust and Institute of Child Health UCL. SLT is supported by a fellowship from The Bath Institute for Rheumatic Diseases and has received previous support from the BMA Doris Hillier Grant (2012). S.L. Tansley, MBChB, MRCP, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust, and University of Bath; Z.E. Betteridge, BSc, PhD, University of Bath; S. Simou, MSc, UCL Institute of Child Health; T.S. Jacques, PhD, MRCP, FRCPath, UCL Institute of Child Health, and GOSH; C. Pilkington, MBBS, FRCPCH, FRCP, GOSH; M. Wood, MBBS, MRCPCH, Leeds Children’s Hospital; K. Warrier, MBBS, MRCPCH, Nottingham University Hospitals NHS Trust; L.R. Wedderburn, MD, PhD, FRCP, UCL Institute of Child Health, and GOSH, and Arthritis Research UK Centre for Adolescent Rheumatology at UCL, UCLH, and GOSH; N.J. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust, and University of Bath. Address correspondence to Dr. S.L. Tansley, Royal National Hospital For Rheumatic Diseases NHS Foundation Trust, Upper Borough Walls, Bath BA1 1RL, UK. E-mail: s.tansley@nhs.net. Accepted for publication December 23, 2016.
Lucy R. Wedderburn
From the Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust; University of Bath, Bath; University College London (UCL) Institute of Child Health; Arthritis Research UK Centre for Adolescent Rheumatology at UCL, University College London Hospitals (UCLH), and Great Ormond Street Hospital (GOSH), London; Leeds Children’s Hospital, Leeds; Nottingham University Hospitals UK National Health Service (NHS) Trust, Nottingham, UK. Funding for the UK Juvenile Dermatomyositis Cohort and Biomarker study has been provided by the Wellcome Trust UK (085860), Action Medical Research UK (SP4252), The Myositis Support Group UK, Arthritis Research UK (14518, 20164), The Henry Smith Charity and Great Ormond Street Children’s Charity (V1268), and the National Institute for Health Research (NIHR) Translational Research Collaboration Rare Diseases. This research was supported by the NIHR Biomedical Research Centre at GOSH for Children NHS Foundation Trust and Institute of Child Health UCL. SLT is supported by a fellowship from The Bath Institute for Rheumatic Diseases and has received previous support from the BMA Doris Hillier Grant (2012). S.L. Tansley, MBChB, MRCP, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust, and University of Bath; Z.E. Betteridge, BSc, PhD, University of Bath; S. Simou, MSc, UCL Institute of Child Health; T.S. Jacques, PhD, MRCP, FRCPath, UCL Institute of Child Health, and GOSH; C. Pilkington, MBBS, FRCPCH, FRCP, GOSH; M. Wood, MBBS, MRCPCH, Leeds Children’s Hospital; K. Warrier, MBBS, MRCPCH, Nottingham University Hospitals NHS Trust; L.R. Wedderburn, MD, PhD, FRCP, UCL Institute of Child Health, and GOSH, and Arthritis Research UK Centre for Adolescent Rheumatology at UCL, UCLH, and GOSH; N.J. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust, and University of Bath. Address correspondence to Dr. S.L. Tansley, Royal National Hospital For Rheumatic Diseases NHS Foundation Trust, Upper Borough Walls, Bath BA1 1RL, UK. E-mail: s.tansley@nhs.net. Accepted for publication December 23, 2016.
Neil J. McHugh
From the Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust; University of Bath, Bath; University College London (UCL) Institute of Child Health; Arthritis Research UK Centre for Adolescent Rheumatology at UCL, University College London Hospitals (UCLH), and Great Ormond Street Hospital (GOSH), London; Leeds Children’s Hospital, Leeds; Nottingham University Hospitals UK National Health Service (NHS) Trust, Nottingham, UK. Funding for the UK Juvenile Dermatomyositis Cohort and Biomarker study has been provided by the Wellcome Trust UK (085860), Action Medical Research UK (SP4252), The Myositis Support Group UK, Arthritis Research UK (14518, 20164), The Henry Smith Charity and Great Ormond Street Children’s Charity (V1268), and the National Institute for Health Research (NIHR) Translational Research Collaboration Rare Diseases. This research was supported by the NIHR Biomedical Research Centre at GOSH for Children NHS Foundation Trust and Institute of Child Health UCL. SLT is supported by a fellowship from The Bath Institute for Rheumatic Diseases and has received previous support from the BMA Doris Hillier Grant (2012). S.L. Tansley, MBChB, MRCP, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust, and University of Bath; Z.E. Betteridge, BSc, PhD, University of Bath; S. Simou, MSc, UCL Institute of Child Health; T.S. Jacques, PhD, MRCP, FRCPath, UCL Institute of Child Health, and GOSH; C. Pilkington, MBBS, FRCPCH, FRCP, GOSH; M. Wood, MBBS, MRCPCH, Leeds Children’s Hospital; K. Warrier, MBBS, MRCPCH, Nottingham University Hospitals NHS Trust; L.R. Wedderburn, MD, PhD, FRCP, UCL Institute of Child Health, and GOSH, and Arthritis Research UK Centre for Adolescent Rheumatology at UCL, UCLH, and GOSH; N.J. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Foundation Trust, and University of Bath. Address correspondence to Dr. S.L. Tansley, Royal National Hospital For Rheumatic Diseases NHS Foundation Trust, Upper Borough Walls, Bath BA1 1RL, UK. E-mail: s.tansley@nhs.net. Accepted for publication December 23, 2016.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Anti-HMGCR Autoantibodies in Juvenile Idiopathic Inflammatory Myopathies Identify a Rare but Clinically Important Subset of Patients
Sarah L. Tansley, Zoe E. Betteridge, Stefania Simou, Thomas S. Jacques, Clarissa Pilkington, Mark Wood, Kishore Warrier, Lucy R. Wedderburn, Neil J. McHugh
The Journal of Rheumatology Feb 2017, jrheum.160871; DOI: 10.3899/jrheum.160871
Anti-HMGCR Autoantibodies in Juvenile Idiopathic Inflammatory Myopathies Identify a Rare but Clinically Important Subset of Patients
Sarah L. Tansley, Zoe E. Betteridge, Stefania Simou, Thomas S. Jacques, Clarissa Pilkington, Mark Wood, Kishore Warrier, Lucy R. Wedderburn, Neil J. McHugh
The Journal of Rheumatology Feb 2017, jrheum.160871; DOI: 10.3899/jrheum.160871